Journal of Clinical Oncology

Reply to: Signal Worth Trusting—If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno

J Juliet Gray (Juliet Gray, PhD, FRCPCH, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom; Rebekah Weston, PhD, FRCPCH, and Simon Gates, PhD, DIC, FHEA, Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, United Kingdom; and Lucas Moreno, MD, PhD, Hospital Vall d'Hebron, Barcelona, Spain) R Rebekah Weston (Juliet Gray, PhD, FRCPCH, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom; Rebekah Weston, PhD, FRCPCH, and Simon Gates, PhD, DIC, FHEA, Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, United Kingdom; and Lucas Moreno, MD, PhD, Hospital Vall d'Hebron, Barcelona, Spain) S Simon Gates (Juliet Gray, PhD, FRCPCH, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom; Rebekah Weston, PhD, FRCPCH, and Simon Gates, PhD, DIC, FHEA, Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, United Kingdom; and Lucas Moreno, MD, PhD, Hospital Vall d'Hebron, Barcelona, Spain) L Lucas Moreno
View Original
APA MLA Chicago BibTeX RIS

Article Details

Volume / Issue Vol. 44, Issue 18
Published June 20, 2026
Pages 1746-1747
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins
ISSN: 0732-183X Health Sciences

Authors (4)

J

Juliet Gray

Juliet Gray, PhD, FRCPCH, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom; Rebekah Weston, PhD, FRCPCH, and Simon Gates, PhD, DIC, FHEA, Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, United Kingdom; and Lucas Moreno, MD, PhD, Hospital Vall d'Hebron, Barcelona, Spain

R

Rebekah Weston

Juliet Gray, PhD, FRCPCH, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom; Rebekah Weston, PhD, FRCPCH, and Simon Gates, PhD, DIC, FHEA, Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, United Kingdom; and Lucas Moreno, MD, PhD, Hospital Vall d'Hebron, Barcelona, Spain

S

Simon Gates

Juliet Gray, PhD, FRCPCH, Centre for Cancer Immunology, University of Southampton, Southampton, United Kingdom; Rebekah Weston, PhD, FRCPCH, and Simon Gates, PhD, DIC, FHEA, Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, United Kingdom; and Lucas Moreno, MD, PhD, Hospital Vall d'Hebron, Barcelona, Spain

L

Lucas Moreno

Related Articles from this Journal

Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Ismaela Anna Vascotto, Filippo Antonica et al. Aug 2026 10.1200/jco-26-00658

Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial

Samer A. Srour, Jad Chahoud et al. Aug 2026 10.1200/jco-26-00388

Adjuvant Carboplatin for Early-Stage, Triple-Negative Breast Cancer: Taxane and Patient Selection

Risako Komata, Kenju Ando et al. Aug 2026 10.1200/jco-26-00140

Erratum: All-Oral Combination of Revumenib, Decitabine, and Venetoclax for Relapsed or Refractory AML (SAVE)

Ghayas C. Issa, Branko Cuglievan et al. Aug 2026 10.1200/jco-26-01743

Reply to: Prostate-Specific Membrane Antigen Positron Emission Tomography and Radiometabolic Therapies in Metastatic Castration-Resistant Prostate Cancer

Irbaz Bin Riaz, R. Bryan Rumble et al. Aug 2026 10.1200/jco-26-01001